# Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials: 83 (2026)

ClinicalTrials.gov lists 83 trials with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor, 19 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd: 83 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/suzhou-zelgen-biopharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 83
- Recruiting or not yet: 19
- Read on: November 19, 2026

## Trials

The 25 newest of 83, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 22, 2026 | NCT07833839 | ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Not yet recruiting | Neuroendocrine Carcinomas (NEC) | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833839) |
| September 10, 2026 | NCT07813572 | ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Recruiting | Hepatocellular Carcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813572) |
| May 19, 2026 | NCT07595913 | A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Not yet recruiting | Neuroendocrine Carcinoma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595913) |
| May 4, 2026 | NCT07565597 | A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 | Active not recruiting | Healthy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565597) |
| December 2, 2025 | NCT07258121 | Study of ZGGS34 in Participants With Advanced Solid Tumors | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Solid Tumor | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258121) |
| November 17, 2025 | NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive... | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 | Recruiting | Small Cell Lung Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231445) |
| September 24, 2025 | NCT07189455 | Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Recruiting | Small-cell Lung Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189455) |
| August 27, 2025 | NCT07142837 | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07142837) |
| August 1, 2025 | NCT07099547 | Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 | Recruiting | Biliary Tract Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099547) |
| July 23, 2025 | NCT07080216 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Cervical Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07080216) |
| June 26, 2025 | NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Small Cell Lung Cancer, Neuroendocrine Carcinoma | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038096) |
| June 17, 2025 | NCT07024277 | Study of ZG006 in Participants With Neuroendocrine Prostate Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 | Not yet recruiting | Neuroendocrine Prostate Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024277) |
| April 22, 2025 | NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Advanced Solid Tumor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06938880) |
| April 15, 2025 | NCT06927687 | Study of ZG005 in Patients With Advanced Solid Tumors | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 | Active not recruiting | Advanced Solid Tumor | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06927687) |
| March 30, 2025 | NCT06903377 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06903377) |
| March 19, 2025 | NCT06883526 | Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06883526) |
| September 19, 2024 | NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 | Recruiting | Small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06592638) |
| August 16, 2024 | NCT06558227 | Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 | Unknown | Hepatocellular Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558227) |
| June 3, 2024 | NCT06440057 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion... | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Neuroendocrine Carcinoma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06440057) |
| April 18, 2024 | NCT06372626 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Unknown | Neuroendocrine Carcinoma | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06372626) |
| February 28, 2024 | NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion... | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Recruiting | Small Cell Lung Cancer, Neuroendocrine Cancer | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06283719) |
| February 7, 2024 | NCT06246695 | A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06246695) |
| February 5, 2024 | NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Unknown | Cervical Carcinoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06241235) |
| February 2, 2024 | NCT06239298 | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Unknown | Solid Tumor | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239298) |
| February 1, 2024 | NCT06237413 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1/2 | Unknown | Solid Tumor, KRAS Mutation-Related Tumors | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06237413) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 29 |
| Phase 2 | 19 |
| Phase 2/3 | 1 |
| Phase 3 | 16 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 38 |
| Unknown | 15 |
| Recruiting | 15 |
| Terminated | 8 |
| Not yet recruiting | 4 |
| Active not recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Neuroendocrine | 7 |
| Primary Myelofibrosis | 7 |
| Small Cell Lung Carcinoma | 6 |
| Dermatitis, Atopic | 4 |
| Alopecia Areata | 4 |
| Spondylitis, Ankylosing | 3 |
| Colorectal Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Carcinoma, Hepatocellular | 2 |
| Uterine Cervical Neoplasms | 2 |
| Idiopathic Pulmonary Fibrosis | 1 |
| Lymphoma | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Stomach Neoplasms | 1 |
| Hepatic Insufficiency | 1 |
| Myelodysplastic Syndromes | 1 |
| Myeloproliferative Disorders | 1 |
| Esophageal Neoplasms | 1 |
| COVID-19 | 1 |
| Pneumonia | 1 |
| Leukemia, Myeloid, Acute | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Courier and delivery companies in the United States](https://specstream.ai/data/businesses/courier-and-delivery-companies/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
- [Genetics practices in the United States](https://specstream.ai/data/businesses/genetics-practices/united-states)
- [Inns in the United States](https://specstream.ai/data/businesses/inns/united-states)
- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Packaging companies in the United States](https://specstream.ai/data/businesses/packaging-companies/united-states)
